The University of Southampton
University of Southampton Institutional Repository

A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma

A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma
The CD20 antigen has become a major therapeutic target in the management of follicular and other Bcell non-Hodgkin’s lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis. In addition, when radioiodinated, the antibody exploits the tumour’s sensitivity to ionising radiation by direct targeting of the malignant cell. Tositumomab and Iodine (I131) tositumomab (Bexxar®, GlaxoSmithKline, Philadelphia, PA, USA) is administered in two steps. The dosimetric step determines individual patient pharmacokinetics, allowing a patient- specific dose to be calculated. This is followed by the therapeutic step, with administration of the therapeutic dose between 7 and 14 days after the dosimetric dose. Over a decade’s worth of experience in clinical trials has determined the efficacy and safety of the regimen in a variety of clinical ci-rcumstances; establishment of exactly where the regimen fits amongst the algorithm for the management of follicular lymphoma continues.
1471-2598
577-588
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Davies, A.J. (2005) A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opinion on Biological Therapy, 5 (4), 577-588. (doi:10.1517/14712598.5.4.577).

Record type: Article

Abstract

The CD20 antigen has become a major therapeutic target in the management of follicular and other Bcell non-Hodgkin’s lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis. In addition, when radioiodinated, the antibody exploits the tumour’s sensitivity to ionising radiation by direct targeting of the malignant cell. Tositumomab and Iodine (I131) tositumomab (Bexxar®, GlaxoSmithKline, Philadelphia, PA, USA) is administered in two steps. The dosimetric step determines individual patient pharmacokinetics, allowing a patient- specific dose to be calculated. This is followed by the therapeutic step, with administration of the therapeutic dose between 7 and 14 days after the dosimetric dose. Over a decade’s worth of experience in clinical trials has determined the efficacy and safety of the regimen in a variety of clinical ci-rcumstances; establishment of exactly where the regimen fits amongst the algorithm for the management of follicular lymphoma continues.

Full text not available from this repository.

More information

Published date: April 2005

Identifiers

Local EPrints ID: 73335
URI: http://eprints.soton.ac.uk/id/eprint/73335
ISSN: 1471-2598
PURE UUID: d058be99-67a5-4208-aeec-7af91752a497

Catalogue record

Date deposited: 11 Mar 2010
Last modified: 06 Dec 2019 17:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×